Biomarkers Identify Patients Who May Benefit From Ezetimibe Therapy
Investigators evaluated the risk for recurrent cardiovascular events and clinical benefit with ezetimibe.
Hannah Dellabella
Contributing Writer https://www.thecardiologyadvisor.com
Hannah Dellabella is a freelance writer for Haymarket Media. She holds an MFA in creative writing from Purdue University and a BA in creative writing and professional writing from Carnegie Mellon University. Previously, she was the associate editor for Clinical Advisor at Haymarket Media and an assistant editor for the Haymarket Medical Network. In addition to being a medical writer, Hannah is a poet whose work has appeared in various literary journals.
